Answers are grounded in this paper and cite their sources.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is biologically heterogeneous. No single bladder-directed therapy addresses every relevant mechanism. Recent reviews have covered pathophysiology, multimodal care, and biomaterial-based mucosal repair in detail. This review takes a different route and uses therapeutic migration as a translational lens. The concept refers to moving a treatment idea from another specialty into IC/BPS when the same biological problem appears to be active in a bladder endotype. Representative migrations include platelet-rich plasma and cell-based repair strategies, along with neural, immune-directed, and microbiome approaches. We also discuss one unsuccessful migration. The central question is whether the biological rationale still holds in the bladder. We therefore propose a migration filter that considers mechanism conservation, endotype enrichment, feasibility in the urinary environment, safety, and objective target engagement. Urothelial healing is discussed as a tissue-recovery construct for bladder-centered phenotypes, while treat-to-target principles are adapted for mechanism-informed research. Therapeutic migration remains the overarching framework, but symptom control and biological recovery are treated as separate outcomes.
No takes yet. Share an insight, caveat, or question.
王建国 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: